ScoreWhy is ACADIA Pharmaceuticals, Inc. ?
1
Poor Management Efficiency with a low ROE of 5.98%
- The company has been able to generate a Return on Equity (avg) of 5.98% signifying low profitability per unit of shareholders funds
2
The company has declared Positive results for the last 6 consecutive quarters
- NET PROFIT(HY) At USD 98.44 MM has Grown at 48.81%
- RAW MATERIAL COST(Y) Fallen by 0.26% (YoY)
- CASH AND EQV(HY) Highest at USD 1,609.01 MM
3
With ROE of 27.01%, it has a attractive valuation with a 4.30 Price to Book Value
- Over the past year, while the stock has generated a return of 28.59%, its profits have risen by 626.7% ; the PEG ratio of the company is 0
4
Rising Promoter Confidence
- Promoters have increased their stake in the company by 0.51% over the previous quarter and currently hold 1.37% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
5
Market Beating Performance
- The stock has generated a return of 28.59% in the last 1 year, much higher than market (S&P 500) returns of 17.78%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to ACADIA Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ACADIA Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
ACADIA Pharmaceuticals, Inc.
28.36%
1.08
47.96%
S&P 500
17.78%
0.92
19.35%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
20.10%
EBIT Growth (5y)
19.37%
EBIT to Interest (avg)
-91.06
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.88
Sales to Capital Employed (avg)
1.46
Tax Ratio
13.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
18.60%
ROE (avg)
5.98%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
4.30
EV to EBIT
30.82
EV to EBITDA
26.76
EV to Capital Employed
38.60
EV to Sales
2.73
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
125.27%
ROE (Latest)
27.01%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
NET PROFIT(HY)
At USD 98.44 MM has Grown at 48.81%
RAW MATERIAL COST(Y)
Fallen by 0.26% (YoY
CASH AND EQV(HY)
Highest at USD 1,609.01 MM
NET SALES(Q)
Highest at USD 278.63 MM
OPERATING PROFIT(Q)
Highest at USD 38.71 MM
OPERATING PROFIT MARGIN(Q)
Highest at 13.89 %
-4What is not working for the Company
PRE-TAX PROFIT(Q)
At USD 44.59 MM has Fallen at -33.41%
DEBTORS TURNOVER RATIO(HY)
Lowest at 8.38 times
Here's what is working for ACADIA Pharmaceuticals, Inc.
Net Profit
At USD 98.44 MM has Grown at 48.81%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Sales
Highest at USD 278.63 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 38.71 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 13.89 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Cash and Eqv
Highest at USD 1,609.01 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by 0.26% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for ACADIA Pharmaceuticals, Inc.
Pre-Tax Profit
At USD 44.59 MM has Fallen at -33.41%
over average net sales of the previous four periods of USD 66.97 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Debtors Turnover Ratio
Lowest at 8.38 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
